The Americas Safety Lancet is marked by the presence of numerous global, regional, and local vendors catering to the demands of a large patient population affected by conditions like diabetes and infectious diseases. This market is highly competitive, with companies both competing and cooperating to capture a significant share. Key drivers of growth include expanding into new, unexplored markets, launching innovative products, forging strategic partnerships, and implementing measures to enhance operational efficiency. Market players employ diverse strategies and advanced research and development techniques to expand their market presence and ensure sustainability.
Mergers and collaborations were also observed to expand the company's product portfolio, as well as introduce new safety lancets. The growth of prominent industry players is dependent on various factors, such as market conditions, FDA approvals, and industry development. It is also projected that a rise in the investments for R&D will also boost the market's growth in the upcoming future.
Major players in the Americas Safety Lancet Market, including Becton, Dickinson and Company, Inc, Dynarex Corporation, Abbott Laboratories, ICU Medical, Inc., Cardinal Health, LifeScan IP Holdings, LLC, and others, are making investments in R&D activities to boost market demand.
In recent years, major players have increasingly engaged in strategic collaborations for product development and geographical expansion into untapped markets to achieve operational excellence and strengthen their market positions in the Americas safety lancet market.
Americas Safety Lancet Industry Developments
September 2022: Tasso has obtained 510(k) clearance for its blood lancet, allowing the company to introduce a device aimed at fulfilling the growing need for remote testing services. Known as Tasso+, this product is engineered to facilitate blood collection in home settings. Users simply adhere the device to their arm and activate it by pressing a button, which deploys a lancet and starts the blood collection process.
In January 2024, the Commission on Primary Health Care (PHC) and Resilience in Latin America and the Caribbean (LAC) was established in January 2024 by the Lancet Americas, the World Bank, and the Pan American Health Organization (PAHO). Its primary objectives are as follows: establish a comprehensive conceptual policy framework for PHC and resilience; identify and define the key investments that LAC countries could undertake; and conduct a thorough assessment of the foreseen consequences. As commissioners, a multidisciplinary group comprising experts, managers, policymakers, and civil society leaders will strive to guarantee substantial technical knowledge, gender parity, and LAC representation.
In November 2023, the Medtronic Symplicity Spyral™ renal denervation system was granted approval by the U.S. Food and Drug Administration (FDA) for distribution within the United States. The system, which has been granted the Breakthrough Device designation by the FDA, disrupts hyperactive neurons in the kidneys via radio frequency in order to assist in the reduction of blood pressure.
There are now, for the first time, medical device-related procedures that have received approval for the treatment of hypertension in the United States. Particularly for those patients whose hypertension does not respond to medication or who have difficulty adhering to their medication regimen, Symplicity Spyral possesses the capacity to significantly impact their lifestyles. When combined with pharmacological interventions and modifications to one's lifestyle, renal denervation presents a viable and secure alternative for the long-term management of hypertension.
The lancet market is significantly driven by the increasing incidence of infectious and chronic diseases, enhanced medical device regulations, growing preference for home healthcare, and the rising prevalence of diabetes.
Key Players in Americas Safety Lancet Market
